Filing Details
- Accession Number:
- 0000899243-23-019274
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-20 06:16:19
- Reporting Period:
- 2023-09-19
- Accepted Time:
- 2023-09-20 06:16:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1885522 | Neumora Therapeutics Inc. | NMRA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1219039 | Keith Crandell | 8755 W. Higgins Road , Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1219042 | Robert Nelsen | 8755 W. Higgins Road , Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1219043 | Clinton Bybee | 8755 W. Higgins Road , Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1229592 | Steven Gillis | 8755 W. Higgins Road , Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1769012 | Arch Venture Partners X, Llc | 8755 W. Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1906837 | Arch Venture Fund Xii, L.p. | 8755 W. Higgins Road , Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1979548 | Arch Venture Partners Xii, Llc | 8755 W. Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1979765 | Arch Venture Partners Xii, L.p. | 8755 W. Higgins Road , Suite 1025 Chicago IL 60631 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-09-19 | 684,167 | $0.00 | 684,167 | No | 4 | C | Indirect | By ARCH Venture Fund VII, L.P. |
| Common Stock | Acquisiton | 2023-09-19 | 1,144,973 | $0.00 | 1,144,973 | No | 4 | C | Indirect | By ARCH Venture Fund VIII Overage, L.P. |
| Common Stock | Acquisiton | 2023-09-19 | 6,895,021 | $0.00 | 12,205,379 | No | 4 | C | Indirect | By ARCH Venture Fund X, L.P. |
| Common Stock | Acquisiton | 2023-09-19 | 6,576,400 | $0.00 | 11,886,758 | No | 4 | C | Indirect | By ARCH Venture Fund X Overage, L.P. |
| Common Stock | Acquisiton | 2023-09-19 | 2,124,143 | $0.00 | 2,124,143 | No | 4 | C | Indirect | By ARCH Venture Fund XII, L.P. |
| Common Stock | Acquisiton | 2023-09-19 | 1,500,000 | $17.00 | 3,624,143 | No | 4 | P | Indirect | By ARCH Venture Fund XII, L.P. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By ARCH Venture Fund VII, L.P. |
| No | 4 | C | Indirect | By ARCH Venture Fund VIII Overage, L.P. |
| No | 4 | C | Indirect | By ARCH Venture Fund X, L.P. |
| No | 4 | C | Indirect | By ARCH Venture Fund X Overage, L.P. |
| No | 4 | C | Indirect | By ARCH Venture Fund XII, L.P. |
| No | 4 | P | Indirect | By ARCH Venture Fund XII, L.P. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Preferred Stock | Disposition | 2023-09-19 | 684,167 | $0.00 | 684,167 | $0.00 |
| Common Stock | Series A-1 Preferred Stock | Disposition | 2023-09-19 | 1,144,973 | $0.00 | 1,144,973 | $0.00 |
| Common Stock | Series A-2 Preferred Stock | Disposition | 2023-09-19 | 6,895,021 | $0.00 | 6,895,021 | $0.00 |
| Common Stock | Series A-2 Preferred Stock | Disposition | 2023-09-19 | 6,576,400 | $0.00 | 6,576,400 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2023-09-19 | 2,124,143 | $0.00 | 2,124,143 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
- Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
- Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
- Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
- Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
- ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.
- Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Billionaire Hedge Funds
